Pharmacokinetic interaction of the antiparasitic agents ivermectin and spinosad in dogs

Drug Metabolism and Disposition

Volumn 39, Issue 5, 2011, Pages 789-795

  Dunn, Stewart T ^a,c   Hedges, Laura ^a,c   Sampson, Kathleen E ^a,c   Lai, Yurong ^a,c   Mahabir, Sean ^b,c   Balogh, Larissa ^a,c   Locuson, Charles W ^a,c  

^a PFIZER INC   (United States)

^b Biometrics   (United States)

^c ZOETIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; CALCEIN ACETOXYMETHYL ESTER; COMFORTIS; DIGOXIN; FLUORESCENT DYE; GLYCOPROTEIN P; IVERMECTIN; MULTIDRUG RESISTANCE PROTEIN 1; SPINOSAD; SPINOSYN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG TRANSPORT; GENETIC TRANSFECTION; IC 50; IN VIVO STUDY; KIDNEY CELL; MAXIMUM PLASMA CONCENTRATION; METABOLIC INHIBITION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECRETORY PATHWAY; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIPARASITIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CELL LINE; DIGOXIN; DOGS; DRUG COMBINATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUORESCEINS; HUMANS; IVERMECTIN; MACROLIDES; P-GLYCOPROTEIN; RANDOM ALLOCATION;

CANIS FAMILIARIS; SIPHONAPTERA (FLEAS);

EID: 79955006122     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034827     Document Type: Article

References (42)

1. Ballent M, Lifschitz A, Virkel G, Sallovitz J, and Lanusse C (2006) Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: In vitro and in vivo assessments. Drug Metab Dispos 34:457-463. (Pubitemid 43290904)
2. Campbell WC, Fisher MH, Stapley EO, Albers-Schönberg G, and Jacob TA (1983) Ivermectin: A potent new antiparasitic agent. Science 221:823-828. (Pubitemid 13034281)
3. Chen C, Liu X, and Smith BJ (2003) Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr Drug Metab 4:272-291. (Pubitemid 36958329)
4. Daurio CP, Cheung EN, Jeffcoat AR, and Skelly BJ (1992) Bioavailability of ivermectin administered orally to dogs. Vet Res Commun 16:125-130.
5. del Amo EM, Heikkinen AT, and Mönkkönen J (2009) In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption. Eur J Pharm Sci 36:200-211.
6. Didier A and Loor F (1996) The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anticancer Drugs 7:745-751. (Pubitemid 26388764)
7. Environmental Protection Agency (1999) Spinosad; pesticide tolerance. Fed Regist 64:51451-51460.
8. Fecht S and Distl O (2008) Review of prevalence, genetic aspects and adverse effects of the mdr1-1Delta mutation in dogs. Dtsch Tierarztl Wochenschr 115:212-219. (Pubitemid 351879019)
9. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, and de Morais SM (2008) In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36:268-275. (Pubitemid 351185738)
10. Geary TG (2005) Ivermectin 20 years on: Maturation of a wonder drug. Trends Parasitol 21:530-532. (Pubitemid 41447026)
11. Gokbulut C, Karademir U, Boyacioglu M, and McKellar QA (2006) Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. Vet Parasitol 135:347-354. (Pubitemid 43117016)
12. González Canga A, Sahagún Prieto AM, Josí Diez Liíbana M, Martínez NF, Vega MS, and Vieitez JJ (2009) The pharmacokinetics and metabolism of ivermectin in domestic animal species. Vet J 179:25-37.
13. Ho RH and Kim RB (2005) Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther 78:260-277. (Pubitemid 41254111)
14. Hopkins KD, Marcella KL, and Strecker AE (1990) Ivermectin toxicosis in a dog. J Am Vet Med Assoc 197:93-94. (Pubitemid 20313439)
15. Hugnet C, Lespine A, and Alvinerie M (2007) Multiple oral dosing of ketoconazole increases dog exposure to ivermectin. J Pharm Pharm Sci 10:311-318. (Pubitemid 350055593)
16. Kalgutkar AS, Frederick KS, Chupka J, Feng B, Kempshall S, Mireles RJ, Fenner KS, and Troutman MD (2009) N-(3,4-Dimethoxyphenethyl)-4-(6,7-dimethoxy-3, 4-dihydroisoquinolin- 2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat. J Pharm Sci 98:4914-4927.
17. Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, and Yokoi T (2006) Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharm Sci 95:2673-2683. (Pubitemid 46093174)
18. Kiki-Mvouaka S, Mínez C, Borin C, Lyazrhi F, Foucaud-Vignault M, Dupuy J, Collet X, Alvinerie M, and Lespine A (2010) Role of P-glycoprotein in the disposition of macrocyclic lactones: A comparison between ivermectin, eprinomectin, and moxidectin in mice. Drug Metab Dispos 38:573-580.
19. Kojima K, Yamamoto K, and Nakanishi Y (1987) Determination of 22,23-dihydroavermectin B1a in dog plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr Biomed Appl 413:326-331. (Pubitemid 17005028)
20. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, Keohane CA, Ly VT, Strauss JR, Wang RW, Wang Z, et al. (1999) Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 27:581-587. (Pubitemid 29214469)
21. Laffont CM, Toutain PL, Alvinerie M, and Bousquet-Mílou A (2002) Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab Dispos 30:626-630. (Pubitemid 34579093)
22. Lo PK, Fink DW, Williams JB, and Blodinger J (1985) Pharmacokinetic studies of ivermectin: Effects of formulation. Vet Res Commun 9:251-268. (Pubitemid 16239520)
23. Lovell RA (1990) Ivermectin and piperazine toxicoses in dogs and cats. Vet Clin North Am Small Anim Pract 20:453-468. (Pubitemid 20128295)
24. Martinez M, Modric S, Sharkey M, Troutman L, Walker L, and Mealey K (2008) The pharmacogenomics of P-glycoprotein and its role in veterinary medicine. J Vet Pharmacol Ther 31:285-300. (Pubitemid 352000159)
25. Mealey KL (2004) Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 27:257-264. (Pubitemid 39482230)
26. Mealey KL, Bentjen SA, Gay JM, and Cantor GH (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11:727-733. (Pubitemid 33078243)
27. Mealey KL and Meurs KM (2008) Breed distribution of the ABCB1-1δ (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc 233:921-924.
28. Mueller RS (2004) Treatment protocols for demodicosis: An evidence-based review. Vet Dermatol 15:75-89. (Pubitemid 38482372)
29. Murakami T and Takano M (2008) Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 4:923-939.
30. Omura S (2008) Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 31:91-98.
31. Plumb DC (2005) Plumb's Veterinary Drub Handbook, Blackwell Publishing Professional, Ames, IA.
32. Pulliam J, Seward R, Henry R, and Steinberg S (1985) Investigating ivermectin toxicity in collies. Vet Med 7:33-40.
33. Raymond V and Sattelle DB (2002) Novel animal-health drug targets from ligand-gated chloride channels. Nat Rev Drug Discov 1:427-436. (Pubitemid 37361485)
34. Rutherford BS, Gardner RC, West SD, Robb CK, and Dolder SC (2000) Residues of spinosad in meat, milk, and eggs. J Agric Food Chem 48:4428-4431.
35. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, and te Riele HP (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502. (Pubitemid 24153990)
36. Sherman JG, Paul AJ, and Firkins LD (2010) Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation. Am J Vet Res 71:115-119.
37. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035. (Pubitemid 27113956)
38. Suzuyama N, Katoh M, Takeuchi T, Yoshitomi S, Higuchi T, Asashi S, and Yokoi T (2007) Species differences of inhibitory effects on P-glycoprotein- mediated drug transport. J Pharm Sci 96:1609-1618. (Pubitemid 46953775)
39. Tiberghien F and Loor F (1996) Ranking of P-glycoprotein substrates and inhibitors by a calcein AM fluorometry screening assay. Anticancer Drugs 7:568-578. (Pubitemid 26276348)
40. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
41. Wolstenholme AJ and Rogers AT (2005) Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology 131 (Suppl):S85-S95.
42. Yates DM, Portillo V, and Wolstenholme AJ (2003) The avermectin receptors of Haemonchus contortus and Caenorhabditis elegans. Int J Parasitol 33:1183-1193. (Pubitemid 37101465)